Market atlas / NAD+ precursors / NMN
NMN (NAD+ precursor)
traditional-to-validatedsmall-moleculenad-precursorsirtuin-support● nad-levels
Stage by geography
signalpreclinfirst-in-humanRCTapprovedreal-worldconsumerUSCNSG+3 stages
MarketsUS United States FDAUK United Kingdom MHRA / NICECN China NMPAIN India CDSCOJP Japan PMDACH Switzerland SwissmedicSG Singapore HSAIL Israel Ministry of HealthKR South Korea MFDS
What each market approved it for
| Market | Stage | Since | Indication / class / form |
|---|---|---|---|
| US | consumer | not dated | not published |
| CN | RCT | 2024-05-01 | not published |
| SG | signal | not dated | not published |
Legal status by market
| Market | Legal class | Effective | Status & source |
|---|---|---|---|
| US | Dietary supplement | 2025-09-29 | Not excluded from the US dietary-supplement definition: FDA reversed its 2022 drug-preclusion position, finding NMN was marketed as a supplement from 2017, before it was authorized for investigation as a new drug (response to citizen petition FDA-2023-P-0872, 29 Sep 2025). |
Biomarker trends
no biomarker readings yet
Studies
The studies on NMN, what they found, in whom and how strongly, are on its evidence page, each linked to its source.
What the trials measure
Registered primary outcomes this development's trials are powered on, commonest first (ClinicalTrials.gov). What is measured, across markets.
| Registered primary endpoint | Markets measuring it |
|---|---|
| Evaluation of overall efficacy response after nicotinamide adenine dinucleotide/NMN treatment within 2 weeks | CN |
| Incidence of treatment-emergent Adverse Events and TRAE | CN |
| The comparison of the gut microbiota composition | CN |
| The alterations of gut metabolites | CN |
| Blood sugar level | CN |
| Fasting insulin | CN |
| Endocrine hormones including AMH | CN |
| Ovarian volume | CN |
| Follicle number | CN |
| Blood NAD+ level | CN |
Connections
no connections yet
Trajectory
2025
Legal statusUS: dietary supplement. Not excluded from the US dietary-supplement definition: FDA reversed its 2022 drug-preclusion position, finding NMN was marketed as a supplement from 2017, before it was authorized for investigation as a new drug (response to citizen petition FDA-2023-P-0872, 29 Sep 2025).
FDA-2023-P-0872-2754 · machine-extracted
Get into the weeds: raw observations + provenance
nmn_cn 2026-06-29 kind=geography_stage verify=M NMN: registered phase 2 trials in China [NCT05882214] source NCT05882214 https://clinicaltrials.gov/study/NCT05882214 nmn_facets 2026-06-29 kind=facets verify=M NMN facets source NCT06882096 https://clinicaltrials.gov/study/NCT06882096 nmn_us_trial 2026-06-29 kind=geography_stage verify=M NMN: US early-phase clinical trials [NCT06882096] source NCT06882096 https://clinicaltrials.gov/study/NCT06882096 legal__US__dev_nmn__2026-10-01 2026-10-01 kind=legal_status verify=M dev_nmn in US: dietary-supplement (Not excluded from the US dietary-supplement definition: FDA reversed its 2022 drug-preclusion position, finding NMN was marketed as a supplement from 2017, before it was authorized for investigation as a new drug (response to citizen petition FDA-2023-P-0872, 29 Sep 2025).) source FDA-2023-P-0872-2754 https://www.regulations.gov/document/FDA-2023-P-0872-2754 ctsearch__SG__dev_nmn 2026-07-10 kind=geography_stage verify=M nicotinamide mononucleotide: 1 registered trial(s) in SG, highest phase ? [NCT07451496] source NCT07451496 https://clinicaltrials.gov/study/NCT07451496 nmn_us__2026-10-01 2026-10-01 kind=geography_stage verify=M NMN sold as a US dietary supplement source DSLD:285371 https://dsld.od.nih.gov/label/285371